WEKO3
アイテム
{"_buckets": {"deposit": "0a104d4e-6daa-4fa6-b7bf-c066526e7867"}, "_deposit": {"created_by": 1, "id": "80587", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "80587"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00080587", "sets": ["1"]}, "author_link": ["1002329", "1002326", "1002325", "1002322", "1002328", "1002327", "1002331", "1002323", "1002330", "1002324"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "12", "bibliographicPageStart": "2914", "bibliographicVolumeNumber": "25", "bibliographic_titles": [{"bibliographic_title": "Molecules (Basel, Switzerland)"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Rociletinib (CO-1686), a 2,4-diaminopyrimidine derivative, is a highly potent tyrosine kinase inhibitor (TKI) that acts on epidermal growth factor receptor (EGFR) with L858R/T790M mutations. We supposed radioiodinated CO-1686 would function as a useful tool for monitoring EGFR L858R/T790M mutations. To aid in patient selection before therapy with EGFR-TKIs, this study aimed to develop a I-labeled derivative of CO-1686, -{3-[(2-{[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]amino}-5-(trifluoromethyl)pyrimidine-4-yl] amino}-5-([I]iodophenyl)acrylamide ([I]ICO1686) and evaluate its selectivity toward EGFR L858R/T790M. Radiosynthesis was performed by iododestannylation of the corresponding tributylstannyl precursor with [I]NaI and -chlorosuccinimide. The selectivity of the tracer for detecting EGFR L858R/T790M was evaluated using three relevant non-small cell lung cancer (NSCLC) cell lines-H1975, H3255 and H441 overexpressing the dual mutation EGFR L858R/T790M, active mutant EGFR L858R and wild-type EGFR, respectively. The nonradioactive ICO1686 and the precursor compound were successfully synthesized. A novel radiolabeled probe, [I]ICO1686, was prepared with high radiochemical yield (77%) and purity (\u003e99%). ICO1686 exhibited high cytotoxicity toward H1975 (IC 0.20 ± 0.05 μM) and H3255 (IC 0.50 ± 0.21 μM), which is comparable to that of CO-1686. In contrast, the cytotoxicity of ICO1686 toward H441 was 10-fold lower than that toward H1975. In the cell uptake study, the radioactivity uptake of [I]ICO1686 in H1975 was 101.52% dose/mg, whereas the uptakes in H3255 and H441 were 33.52 and 8.95% dose/mg, respectively. The uptake of [I]ICO1686 in H1975 was greatly reduced to 45.61% dose/mg protein by treatment with excess CO-1686. In vivo biodistribution study of the radiotracer found that its accumulation in H1975 tumor (1.77 ± 0.43% ID/g) was comparable to that in H3255 tumor (1.63 ± 0.23% ID/g) and the accumulation in H1975 tumor was not reduced by pretreatment with an excess dose of CO-1686. Although this radiotracer exhibited highly specific in vitro uptake in target cancer cells, structural modification is required to improve in vivo biodistribution.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "MDPI"}]}, "item_8_relation_13": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "32599930", "subitem_relation_type_select": "PMID"}}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3390/molecules25122914", "subitem_relation_type_select": "DOI"}}]}, "item_8_relation_17": {"attribute_name": "関連サイト", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.3390/molecules25122914", "subitem_relation_type_select": "DOI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1420-3049", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Fawwaz, Muammar"}], "nameIdentifiers": [{"nameIdentifier": "1002322", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mishiro, Kenji"}], "nameIdentifiers": [{"nameIdentifier": "1002323", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishii, Ryuichi"}], "nameIdentifiers": [{"nameIdentifier": "1002324", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sawazaki, Izumi"}], "nameIdentifiers": [{"nameIdentifier": "1002325", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shiba, Kazuhiro"}], "nameIdentifiers": [{"nameIdentifier": "1002326", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kinuya, Seigo"}], "nameIdentifiers": [{"nameIdentifier": "1002327", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ogawa, Kazuma"}], "nameIdentifiers": [{"nameIdentifier": "1002328", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ryuichi, Nishii", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1002329", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kazuhiro, Shiba", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1002330", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Seigo, Kinuya", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1002331", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR)", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR)"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/80587", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-09-30"}, "publish_date": "2020-09-30", "publish_status": "0", "recid": "80587", "relation": {}, "relation_version_is_last": true, "title": ["Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR)"], "weko_shared_id": -1}
Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR)
https://repo.qst.go.jp/records/80587
https://repo.qst.go.jp/records/80587ccf24a81-e33e-4e65-9da0-30060427c25b
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-09-30 | |||||
タイトル | ||||||
タイトル | Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR) | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Fawwaz, Muammar
× Fawwaz, Muammar× Mishiro, Kenji× Nishii, Ryuichi× Sawazaki, Izumi× Shiba, Kazuhiro× Kinuya, Seigo× Ogawa, Kazuma× Ryuichi, Nishii× Kazuhiro, Shiba× Seigo, Kinuya |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Rociletinib (CO-1686), a 2,4-diaminopyrimidine derivative, is a highly potent tyrosine kinase inhibitor (TKI) that acts on epidermal growth factor receptor (EGFR) with L858R/T790M mutations. We supposed radioiodinated CO-1686 would function as a useful tool for monitoring EGFR L858R/T790M mutations. To aid in patient selection before therapy with EGFR-TKIs, this study aimed to develop a I-labeled derivative of CO-1686, -{3-[(2-{[4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl]amino}-5-(trifluoromethyl)pyrimidine-4-yl] amino}-5-([I]iodophenyl)acrylamide ([I]ICO1686) and evaluate its selectivity toward EGFR L858R/T790M. Radiosynthesis was performed by iododestannylation of the corresponding tributylstannyl precursor with [I]NaI and -chlorosuccinimide. The selectivity of the tracer for detecting EGFR L858R/T790M was evaluated using three relevant non-small cell lung cancer (NSCLC) cell lines-H1975, H3255 and H441 overexpressing the dual mutation EGFR L858R/T790M, active mutant EGFR L858R and wild-type EGFR, respectively. The nonradioactive ICO1686 and the precursor compound were successfully synthesized. A novel radiolabeled probe, [I]ICO1686, was prepared with high radiochemical yield (77%) and purity (>99%). ICO1686 exhibited high cytotoxicity toward H1975 (IC 0.20 ± 0.05 μM) and H3255 (IC 0.50 ± 0.21 μM), which is comparable to that of CO-1686. In contrast, the cytotoxicity of ICO1686 toward H441 was 10-fold lower than that toward H1975. In the cell uptake study, the radioactivity uptake of [I]ICO1686 in H1975 was 101.52% dose/mg, whereas the uptakes in H3255 and H441 were 33.52 and 8.95% dose/mg, respectively. The uptake of [I]ICO1686 in H1975 was greatly reduced to 45.61% dose/mg protein by treatment with excess CO-1686. In vivo biodistribution study of the radiotracer found that its accumulation in H1975 tumor (1.77 ± 0.43% ID/g) was comparable to that in H3255 tumor (1.63 ± 0.23% ID/g) and the accumulation in H1975 tumor was not reduced by pretreatment with an excess dose of CO-1686. Although this radiotracer exhibited highly specific in vitro uptake in target cancer cells, structural modification is required to improve in vivo biodistribution. | |||||
書誌情報 |
Molecules (Basel, Switzerland) 巻 25, 号 12, p. 2914, 発行日 2020-06 |
|||||
出版者 | ||||||
出版者 | MDPI | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1420-3049 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 32599930 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3390/molecules25122914 | |||||
関連サイト | ||||||
識別子タイプ | DOI | |||||
関連識別子 | https://doi.org/10.3390/molecules25122914 |